Tom 10, Nr 2 (2018)
Artykuły
Opublikowany online: 2018-10-03
Wyświetlenia strony
1707
Wyświetlenia/pobrania artykułu
4103
Przydatność biomarkerów w ocenie aktywności nieswoistych chorób zapalnych jelit — wskazówki praktyczne
Gastroenterologia Kliniczna 2018;10(2):52-63.
Streszczenie
Diagnostyka nieswoistych chorób zapalnych jelit (NChZJ) jest złożonym procesem obejmującym zarówno badania laboratoryjne, obrazowe, jak i endoskopowe. W ostatnich latach nastąpił istotny postęp zwłaszcza w zakresie możliwości nieinwazyjnego diagnozowania i monitorowania aktywności NChZJ za pomocą wielu biomarkerów. Obok parametrów powszechnie znanych, takich jak białko C-reaktywne, istnieje także grupa tak zwanych kopromarkerów, których najważniejszy przedstawiciel to kalprotektyna. W niniejszym opracowaniu przedstawiono charakterystykę wybranych biomarkerów, które znajdują zastosowanie w codziennej praktyce klinicznej. Szczególną uwagę poświęcono najbardziej przydatnemu biomarkerowi — kalprotektynie, omawiając jednak także pewne ograniczenia tego badania laboratoryjnego.
Słowa kluczowe: aktywność zapaleniabiałko C-reaktywnebiomarkerykalprotektyna w kalenieswoiste choroby zapalne jelit
Referencje
- Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007; 133(5): 1670–1689.
- Papi C, Fascì-Spurio F, Rogai F, et al. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis. 2013; 45(12): 978–985.
- Lichtenstein G, McGovern D. Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status. The American Journal of Gastroenterology Supplements. 2016; 3(3): 17–26.
- Viennois E, Zhao Y, Merlin D. Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine. Inflamm Bowel Dis. 2015; 21(10): 2467–2474.
- Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology. 2015; 149(5): 1275–1285.e2.
- Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015; 21(40): 11246–11259.
- Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55(3): 426–431.
- Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005; 77(1): 64–77.
- Lehmann FS, Burri E, Beglinger C, et al. The role and utility of faecal markers in inflammatory bowel disease. Ther Adv Gastroenterol. 2015; 8: 23–36.
- D'Angelo F, Felley C, Frossard JL. Calprotectin in Daily Practice: Where Do We Stand in 2017? Digestion. 2017; 95(4): 293–301.
- Judd TA, Day AS, Lemberg DA, et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011; 26(10): 1493–1499.
- Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016; 9: 21–29.
- Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutierrez L, et al. Neutrophil Extracellular Traps and Its Implications in Inflammation: An Overview. Front Immunol. 2017; 8: 81.
- Eder P, Stawczyk-Eder K, Krela-Kaźmierczak I, et al. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease. Pol Arch Med Wewn. 2008; 118(11): 622–626.
- Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013; 17(55): xv–xix, 1.
- Brookes MJ, Whitehead S, Gaya DR, et al. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol. 2018; 9(2): 87–91.
- Whitehead SJ, Ford C, Gama RM, et al. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol. 2017; 70(12): 1049–1056.
- Theede K, Holck S, Ibsen P, et al. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2015; 13(11): 1929–19236.e1.
- Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105(1): 162–169.
- Stawczyk-Eder K, Eder P, Lykowska-Szuber L, et al. Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study. Arch Med Sci. 2015; 11(2): 353–361.
- Zittan E, Kelly OB, Kirsch R, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease. Inflamm Bowel Dis. 2016; 22(3): 623–630.
- Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis. 2017; 23(6): 894–902.
- Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015; 9(1): 33–40.
- Louis E, Mary JY, Vernier-Massouille G, et al. Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012; 142(1): 63–70.e5; quiz e31.
- Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis. 2015; 9(1): 1–3.
- Lasson A, Öhman L, Stotzer PO, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterol J. 2015; 3(1): 72–79.
- Nguyen GC, Loftus EV, Hirano I, et al. AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. Gastroenterology. 2017; 152(1): 271–275.
- Łodyga M, Eder P, Bartnik W, et al. Wytyczne Grupy Roboczej Konsultanta Krajowego w dziedzinie ogii i Polskiego Towarzystwa ogii dotyczące postępowania z pacjentem z chorobą Leśniowskiego-Crohna. Prz Gastroenterol. 2012; 7: 317–338.
- Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015; 148(5): 938–947.e1.
- Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn's disease: is colonoscopic surveillance no longer needed? Gastroenterology. 2015; 148(5): 889–892.
- Sipponen T, Haapamäki J, Savilahti E, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012; 47(7): 778–784.
- Olsen PAS, Fossmark R, Qvigstad G. Fecal calprotectin in patients with suspected small bowel disease--a selection tool for small bowel capsule endoscopy? Scand J Gastroenterol. 2015; 50(3): 272–277.
- Arai T, Takeuchi K, Miyamura M, et al. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography. Clin Gastroenterol Hepatol. 2017; 15(1): 56–62.
- Li F, Ma J, Geng S, et al. Fecal calprotectin concentrations in healthy children aged 1-18 months. PLoS One. 2015; 10(3): e0119574.
- Zhu Q, Li F, Wang J, et al. Fecal calprotectin in healthy children aged 1-4 years. PLoS One. 2016; 11(3): e0150725.
- Naismith GD, Smith LA, Barry SJE, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013; 37(6): 613–621.
- Lasson A, Stotzer PO, Öhman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015; 9(1): 26–32.
- Du L, Foshaug R, Huang VW, et al. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease: a prospective observational study. J Clin Gastroenterol. 2018; 52(3): 235–240.
- Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014; 2(1): 30–37.
- Kittanakom S, Shajib MdS, Garvie K, et al. Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017; 2017: 1450970.
- Moniuszko A, Głuszek S, Rydzewska G. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study. Pol Arch Intern Med. 2017; 127(5): 312–318.
- Alibrahim B, Aljasser MI, Salh B. Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review. Can J Gastroenterol Hepatol. 2015; 29(3): 157–163.
- Ohlsson B, Roth B, Larsson E, et al. Calprotectin in serum and zonulin in serum and feces are elevated after introduction of a diet with lower carbohydrate content and higher fiber, fat and protein contents. Biomed Rep. 2017; 6(4): 411–422.
- Eder P, Stawczyk‑Eder K, Łykowska‑Szuber L, et al. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn’s disease. Polish Archives of Internal Medicine. 2013; 124(1-2): 51–57.
